Using dienogest to preserve fertility in women with endometriosis
PFENDO : Ovarian Blockade During Fertility Preservation in Patients With Endometriosis: a Retrospective Non-inferiority Comparative Study
This study is testing if a medication called dienogest can help women with endometriosis collect more healthy eggs during fertility treatments compared to standard methods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 42 Years |
| Sex | Female |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 1 site (Nîmes) |
| Trial ID | NCT06106919 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of dienogest in preserving fertility by comparing the number of mature oocytes collected during ovarian stimulation against conventional protocols using GnRH agonists or antagonists. Endometriosis, affecting a significant number of women, can lead to infertility, making this research crucial for developing effective fertility preservation strategies. The study will involve patients aged 18 to 42 who have undergone ovarian stimulation for fertility preservation while on dienogest treatment. The methodology includes collecting data through surveys to assess quality of life and fertility outcomes.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 to 42 with a diagnosis of endometriosis who have undergone ovarian stimulation for fertility preservation.
Not a fit: Patients seeking fertility preservation for reasons other than endometriosis may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a safer and more effective method for fertility preservation in women with endometriosis.
How similar studies have performed: Previous studies have shown that progestin blockade during ovarian stimulation does not negatively impact the number of oocytes collected, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged between 18 and 42 inclusive * Patient with endometriosis * Patient who has undergone at least one cycle of ovarian stimulation for fertility preservation between June 2022 and September 2023 inclusive, using one of the protocols studied: GnRH agonist GnRH antagonist Dienogest Exclusion Criteria: -Non-medical or medical fertility preservation excluding endometriosis
Where this trial is running
Nîmes
- CHU de Nîmes — Nîmes, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.